Abstract: The present invention refers to a process for producing nano precipitated calcium carbonate (nano-PCC), as well as to the nano precipitated calcium carbonate (nano-PCC) obtained by such a process and a system for producing the nano precipitated calcium carbonate (nano-PCC) comprising at least one dry mill, preferably a dry sandmill. Furthermore, the present invention refers to the use of the nano precipitated calcium carbonate (nano-PCC) as well as to the use of the inventive system for producing nano precipitated calcium carbonate (nano-PCC).

Abstract: The present invention relates to the field of antibodies and their application in food and feedstuff quality control. In particular, the invention relates to a method for the manufacture of an antibody that specifically binds to soy Gly m 8 protein wherein said method comprises immunising an animal with the purified soy Glym8 protein, wherein said soy Glym8 protein has been obtained by expressing soy Glym8 protein in plants, and preferably, tobacco plants and purifying the soy Glym8 protein from said plants and, preferably, tobacco plants and obtaining an antibody from the animal which specifically bind to soy Gly m8 protein, wherein the animal will be sacrificed. Moreover, the invention contemplates an antibody obtained by said method as well as the use of said antibody for detecting soy material in a food preparation or feedstuff preparation. Further, a method for detecting soy material in a food preparation or feedstuff preparation and a kit for carrying out said method are provided.

Abstract: The present invention is directed to a process for producing precipitated calcium carbonate with improved resistance to structural breakdown, wherein the milk of lime is carbonated in the presence of at least one gas other than carbon dioxide, or the carbonation is carried out in the presence of a static gas bubble comminution unit as well as to precipitated calcium carbonate obtained by such a process.

Abstract: The present invention is directed to a process for producing precipitated calcium carbonate with improved resistance to structural breakdown, wherein the milk of lime is carbonated in the presence of at least one gas other than carbon dioxide, or the carbonation is carried out in the presence of a static gas bubble comminution unit as well as to precipitated calcium carbonate obtained by such a process.

Abstract: The present invention is directed to a process for producing precipitated calcium carbonate with improved resistance to structural breakdown, wherein the milk of lime is carbonated in the presence of at least one gas other than carbon dioxide, or the carbonation is carried out in the presence of a static gas bubble comminution unit as well as to precipitated calcium carbonate obtained by such a process.

Abstract: The present invention relates to a process for the preparation of precipitated calcium carbonate allowing for a more sustainable and cost-efficient use of milk of lime. The obtainable products show good optical properties as well as fine particle size distributions.

Abstract: The present invention relates to a process for producing an aqueous suspension of precipitated calcium carbonate, an aqueous suspension of precipitated calcium carbonate and a precipitated calcium carbonate obtained by the process, a process comprising the precipitated calcium carbonate and its use.

Abstract: The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: The invention relates to a compilation comprising at least five different peptides, each peptide comprising at least one sequence element corresponding to an epitope selected from the group consisting of SEQ ID NO.: 1-354, wherein at least five different epitopes are represented. The invention further relates to an in vitro method for determining a patient's immune status to soybean allergens, to a method for detecting at least one soybean allergen in a substance and to a method for determining the allergenicity of a soybean variety. Additionally, the invention relates to a kit comprising at least one composition containing a compound comprising at least five different sequence elements each corresponding to an epitope selected from the group consisting of SEQ ID NO.: 1-354, wherein at least five different epitopes are represented.

Abstract: The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against Plasmodium parasites, including P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.

Abstract: The technology provided herein relates to a novel type of recombinant protein complexes, in particular of antibody-like recombinant fusion protein complexes, hereinafter referred to as immunoassemblins (IAs), suitable as animal and human vaccines comprising a plurality of antigens or antigen domains derived from proteins preferably, but not necessarily presented on the surface of a pathogen. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins and protein complexes; antibodies induced or generated by the use of said vaccines or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: The present invention is directed to a process for producing precipitated calcium carbonate with improved resistance to structural breakdown, wherein the milk of lime is carbonated in the presence of at least one gas other than carbon dioxide, or the carbonation is carried out in the presence of a static gas bubble comminution unit as well as to precipitated calcium carbonate obtained by such a process.

Abstract: The present invention relates to a process for producing an aqueous suspension of precipitated calcium carbonate, an aqueous suspension of precipitated calcium carbonate and a precipitated calcium carbonate obtained by the process, a process comprising the precipitated calcium carbonate and its use.

Abstract: The present invention relates to a process for the preparation of precipitated calcium carbonate allowing for a more sustainable and cost-efficient use of milk of lime. The obtainable products show good optical properties as well as fine particle size distributions.

Abstract: The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against Plasmodium parasites, including P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.

Abstract: The present invention is drawn to a fusion protein containing at least one binding domain that specifically recognizes an eptitope of a plant pathogen and at least one additional domain made from a protein or peptide sequence which is toxic to the pathogen or detrimental the replication, transmission or life cycle of the pathogen. The present invention is further drawn to a pathogenocide made from the binding domain, a cellular targeting sequence and/or membrane localization sequence that leads to membrane anchoring. The present invention is further drawn to nucleotide sequences encoding fusion proteins and pathogenocides and to vectors containing the nucleotide sequences; as well as methods of making the fusion proteins and pathogencides and methods of making pathogen resistant plants, plant cells, or plant tissues with the fusion proteins and pathogenocides.